Pharmaceutical compositions
AssigneeEurasiam Laboratories, Inc.
InventorYoung W. Cho
Life of this patent
Estimating the term…
Abstract
A composition adapted to administer a pharmocologically effective amount of a pharmaceutical agent when ingested orally comprising (a) a pharmaceutical agent; (b) a lipid coating materials; and (c) an enteric coating materials optionally comprising water soluble coating materials; emulsifying and solubilizing agents; binding agents; stabilizing and enzyme inhibiting agents surfactants and antimicrobial agents. The composition can also include a low density lipoprotein composition and lipolytic enzymes.
Claims69
A composition adapted for the oral administration of a selected proteinaceous material in biologically active form, said composition comprising:
- (a) particles having an average diameter of approximately 1 to about 100 microns and consisting essentially of a solid emulsifying agent and a surfactant;
- (b) a selected biologically active proteinaceous material bound to the surface of said particles with a binder agent;
- and
- (c) a lipid coating having a thickness of approximately 0.05 to about 1.0 microns surrounding said particles having said proteinaceous material bound to their surfaces.
A composition adapted for the oral administration of insulin in biologically active form, said composition comprising:
- (a) particles having an average diameter of from about 1 to about 100 microns and consisting essentially of cholesterol, sodium lauryl sulfate and, methyl and propylparabens;
- (b) insulin bound to the surface of said particles with a solution consisting essentially of hydroxypropylcellulose, sodium lauryl sulfate, triethylamine HCl and citric acid;
- (c) a lipid coating having a thickness of from about 0.1 to 0.3 microns;
- and
- (d) an enteric coating layer comprising hydroxypropylmethylcellulose phthalate, shellac and PEG-6000 with the thickness of 0.1 microns surrounding said polyethylene glycol monostearate coating on said particles.
A method for the preparation of compositions adapted for oral administration of selected proteinaceous material in biologically active form comprising the steps:
- (a) forming particles having an average diameter of from about 1 micron to 1/2 millimeter and consisting essentially of a solid emulsifying agent and a surfactant;
- (b) binding a selected biologically active proteinaceous material to the surfaces of said particles with a binder agent;
- and
- (c) coating said particles having said proteinaceous material bound to their surfaces with a lipid coating layer having a thickness of 0.05 to 1.0 microns.
A composition adapted for the oral administration of insulin in biologically active form comprising:
- particles having an average diameter of approximately 1 to 100 microns consisting essentially of an emulsifying agent and a surfactant;
- insulin bound to the surface of the particles;
- a lipid coating surrounding the particles having the proteinaceous material bond to their surfaces;
- and
- an enteric coating layer surrounding the lipid coating.
A method of orally administering insulin comprising:
- providing a composition for oral ingestion comprising insulin bound to a surface of a solid emulsifier/solubilizing particle, the insulin and particles being coated with a lipid coating, the particles having an average diameter of approximately 1 micron to about 100 microns, and the lipid coating being coated by an enteric coating.
A method orally administering insuling composition:
- providing a composition for oral ingestion comprising insulin bound to a surface of lipoprotein particles, the insulin and particles being coated by a lipid coating, and the lipid coating being coated by an enteric coating.
A composition adapted for the oral administration of a selected proteinaceous material in biologically active form, said composition comprising:
- (a) a lipoprotein composition;
- (b) a selected biologically active proteinaceous material bound to the surface of the lipoprotein composition;
- and
- (c) a lipid coating surrounding said lipoprotein composition and proteinaceous material.
A composition adapted for the oral administration of insulin in biologically active form, said composition comprising:
- (a) particles having an average diameter of from about 1 micron to about 1/2 millimeter and including a low density of lipoprotein composition;
- (b) insulin bound to the surface of said particles with a binder;
- (c) a water soluble coating layer, for coating the particles and insulin;
- and
- (d) a lipid coating for coating the water soluble layer, particles and insulin.
A method for the preparation of compositions adapted for the oral administration of selected proteinaceous material in biologically active form comprising the steps of:
- (a) forming low density lipoprotein particles having an average diameter of from about 1 micron to 1/2 millimeter;
- (b) binding a selected biologically active proteinaceous material to the surfaces of said particles with a binder agent;
- (c) coating the particles and proteinaceous material with a water soluble coating;
- and
- (d) coating the water soluble coated particles having said proteinaceous material bound to their surfaces with a lipid coating layer having a thickness of 0.05 to 1.0 microns.
A composition adapted for the oral administration of insulin in biologically active form comprising:
- low density lipoprotein particles;
- insulin bound to the surface of the particles;
- a water soluble coating surrounding the particles and insulin;
- a lipid coating surrounding the water soluble coating and particles having insulin bound to their surfaces;
- a gel capsule for surrounding the lipid coating;
- and
- an enteric coating layer surrounding the gel capsule.
A method of treating diabetes comprising the steps of:
- administering orally at least one capsule having a composition including a low density lipoprotein, insulin bound to the lipoprotein, a water soluble coating over the insulin and lipoprotein, and a lipid coating over the water soluble coating;
- and
- administering orally at least one capsule having a composition icluding lipolytic enzymes and bile salts.
The method of treating diabetes comprising the steps of:
- administering orally at least one capsule having a composition including emulsifier/solubilizer particles, insulin bound to the particles, and a lipid coating over the particles;
- and
- administering orally at least one capsule having a composition including lipolytic enzymes.
A composition useful for the oral administration of a proteinaceous compound comprising lipolytic enzymes selected from the group including, pancreatic lipase, amylase, protease, and bile salts.
A composition adapted for the oral administration of insulin comprising the following components:
- (a) particles of pancreatic lipase;
- (b) particles of bile salt;
- (c) lipid coated insulin bound lipid particles;
- (d) sodium bicarbonate;
- and
- (e) citric acid.
A composition adapted for the oral administration of insulin comprising a sodium bicarbonate and citric acid mixture in a ratio of approximately 3:1 to about 1:1, the mixture forming a seed that is coated with a layer of an insulin lipid mixture, and a resultant particle is then coated with an enteric coating.
Dependencies are inferred from the claim text.